Antibody could be first new lupus drug in 50 years

An antibody that targets B cells has moved a step closer to becoming the newest lupus treatment in over half a century, after meeting its primary end point in a second pivotal Phase III trial.

by
Belimumab acts on B cells. Autoantibodies produced by these cells contribute to the pathogenesis of lupus.
Belimumab acts on B cells. Autoantibodies produced by these cells contribute to the pathogenesis of lupus.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package